# Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

> **NCT00002080** · NA · COMPLETED · sponsor: **Pharmacia**

## Conditions studied

- Mycobacterium Avium-intracellulare Infection
- HIV Infections

## Interventions

- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT00002080
- **Lead sponsor:** Pharmacia
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002080, "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00002080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*